Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS

Anna K. Bytzek, E. Enyedy, T. Kiss, Bernhard K. Keppler, Christian G. Hartinger

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Application of modern analytical technology for studying the fate of metallodrugs after administration to the blood is of utmost importance for drug development. Zn(II) compounds are under development as insulin-enhancing drugs with potential use in the treatment of diabetes. In comparison to the well-established vanadium compounds, especially the lower risk of adverse effects due to the essentiality of the element in biological processes is advantageous. Herein, CZE-ICP-MS studies on the interaction of Zn(II)-maltolato, -2-picolinato and -2,6-dipicolinato complexes with human serum proteins are discussed and modeling calculations were confirmed by experimental results. Studies with human serum reveal preference for HSA over other less abundant proteins and serum components.

Original languageEnglish
Pages (from-to)4075-4082
Number of pages8
JournalElectrophoresis
Volume30
Issue number23
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Protein Binding
Blood Proteins
Vanadium Compounds
Biological Phenomena
Medical problems
Serum
Pharmaceutical Preparations
Blood
Insulin
Technology
In Vitro Techniques

Keywords

  • Anti-diabetic Zn(II) complexes
  • CE
  • ICP-MS
  • Protein interactions
  • Speciation in blood serum

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS. / Bytzek, Anna K.; Enyedy, E.; Kiss, T.; Keppler, Bernhard K.; Hartinger, Christian G.

In: Electrophoresis, Vol. 30, No. 23, 12.2009, p. 4075-4082.

Research output: Contribution to journalArticle

Bytzek, Anna K. ; Enyedy, E. ; Kiss, T. ; Keppler, Bernhard K. ; Hartinger, Christian G. / Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS. In: Electrophoresis. 2009 ; Vol. 30, No. 23. pp. 4075-4082.
@article{f9091b7b6b2441cdb101035617dc651c,
title = "Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS",
abstract = "Application of modern analytical technology for studying the fate of metallodrugs after administration to the blood is of utmost importance for drug development. Zn(II) compounds are under development as insulin-enhancing drugs with potential use in the treatment of diabetes. In comparison to the well-established vanadium compounds, especially the lower risk of adverse effects due to the essentiality of the element in biological processes is advantageous. Herein, CZE-ICP-MS studies on the interaction of Zn(II)-maltolato, -2-picolinato and -2,6-dipicolinato complexes with human serum proteins are discussed and modeling calculations were confirmed by experimental results. Studies with human serum reveal preference for HSA over other less abundant proteins and serum components.",
keywords = "Anti-diabetic Zn(II) complexes, CE, ICP-MS, Protein interactions, Speciation in blood serum",
author = "Bytzek, {Anna K.} and E. Enyedy and T. Kiss and Keppler, {Bernhard K.} and Hartinger, {Christian G.}",
year = "2009",
month = "12",
doi = "10.1002/elps.200900212",
language = "English",
volume = "30",
pages = "4075--4082",
journal = "Electrophoresis",
issn = "0173-0835",
publisher = "Wiley-VCH Verlag",
number = "23",

}

TY - JOUR

T1 - Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS

AU - Bytzek, Anna K.

AU - Enyedy, E.

AU - Kiss, T.

AU - Keppler, Bernhard K.

AU - Hartinger, Christian G.

PY - 2009/12

Y1 - 2009/12

N2 - Application of modern analytical technology for studying the fate of metallodrugs after administration to the blood is of utmost importance for drug development. Zn(II) compounds are under development as insulin-enhancing drugs with potential use in the treatment of diabetes. In comparison to the well-established vanadium compounds, especially the lower risk of adverse effects due to the essentiality of the element in biological processes is advantageous. Herein, CZE-ICP-MS studies on the interaction of Zn(II)-maltolato, -2-picolinato and -2,6-dipicolinato complexes with human serum proteins are discussed and modeling calculations were confirmed by experimental results. Studies with human serum reveal preference for HSA over other less abundant proteins and serum components.

AB - Application of modern analytical technology for studying the fate of metallodrugs after administration to the blood is of utmost importance for drug development. Zn(II) compounds are under development as insulin-enhancing drugs with potential use in the treatment of diabetes. In comparison to the well-established vanadium compounds, especially the lower risk of adverse effects due to the essentiality of the element in biological processes is advantageous. Herein, CZE-ICP-MS studies on the interaction of Zn(II)-maltolato, -2-picolinato and -2,6-dipicolinato complexes with human serum proteins are discussed and modeling calculations were confirmed by experimental results. Studies with human serum reveal preference for HSA over other less abundant proteins and serum components.

KW - Anti-diabetic Zn(II) complexes

KW - CE

KW - ICP-MS

KW - Protein interactions

KW - Speciation in blood serum

UR - http://www.scopus.com/inward/record.url?scp=72849141591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849141591&partnerID=8YFLogxK

U2 - 10.1002/elps.200900212

DO - 10.1002/elps.200900212

M3 - Article

C2 - 19960475

AN - SCOPUS:72849141591

VL - 30

SP - 4075

EP - 4082

JO - Electrophoresis

JF - Electrophoresis

SN - 0173-0835

IS - 23

ER -